MRNA - Moderna Inc logo

Moderna Inc

MRNA

Moderna develops messenger RNA vaccines and therapeutics targeting infectious diseases, oncology, and rare disorders. Key products include COVID-19 and RSV vaccines, along with treatments for cytomegalovirus and various cancers, serving global healthcare needs.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$621today

Score Overview

1 Year
Score
Net Growth-11.66%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth14.61%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score2.9
Net Growth-125.82%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-87.44%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score
Net Growth-6x
Net Trend38%
Net Income Consistency
Rev Growth18x
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Moderna Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. MRNA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 202.63โ€”
1 Year2025-10-22
$ 26.857x
5 Years2021-10-22
$ 326.54-37.95%
All Time2018-12-07
$ 18.6010x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 2.22B-$ 3.15B$ 5.13B
2025$ 1.94B-$ 2.82B$ 5.79B
2024$ 3.19B-$ 3.56B$ 7.02B
2023$ 6.84B-$ 4.71B$ 8.60B
2022$ 18.87B$ 8.36B$ 9.90B
2021$ 17.73B$ 12.20B$ 10.72B
2020$ 274M-$ 747M$ 4.60B
2019-$ 514M$ 1.10B
IPO2018$ 122M-$ 384M$ 1.69B
MRNA - Moderna Inc logo

Moderna Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 274M to $ 1.94B and net income went from -$ 747M to -$ 2.82B. Revenue increased in 2 of those 5 years; net income in 2.

Moderna Inc currently holds a 5-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.

Membership

Explore MRNA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies